SCHEMBL10195706

SCHEMBL10195706

Cc1ccc(OC2CCOCC2)c(C(F)(F)F)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 1.00
HSD17B1 P14061 1/20 0.43
HSD17B2 P37059 1/20 0.43
PDE4D Q08499 7/20 0.39
PDE4A P27815 7/20 0.39
PDE4B Q07343 5/20 0.39
PDE4C Q08493 5/20 0.39
KAT2B Q92831 1/20 0.39
BAZ2B Q9UIF8 1/20 0.39
FPR2 P25090 2/20 0.38
PROKR1 Q8TCW9 2/20 0.38
GRM2 Q14416 2/20 0.37
HDAC6 Q9UBN7 1/20 0.37
IKBKE Q14164 1/20 0.36
TBK1 Q9UHD2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15801283 0.92 SYK (0.84) SYKPDE4DPDE4APDE4BPDE4C
SCHEMBL12180311 0.92 SYK (0.84) SYKPDE4DPDE4APDE4BPDE4C
SCHEMBL22084562 0.86 SYK (0.76) SYKPDE4DPDE4APDE4BFPR2
SCHEMBL13419182 0.85 SYK (0.74) SYKPDE4DPDE4AFPR2PROKR1
SCHEMBL12180324 0.85 SYK (0.74) SYKPDE4DPDE4APDE4BFPR2
SCHEMBL2795434 0.82 SYK (0.70) SYKPDE4DPDE4APDE4BPDE4C
SCHEMBL14453573 0.82 SYK (0.70) SYKFPR2PROKR1
SCHEMBL12426534 0.81 SYK (0.68) SYKFPR2PROKR1
SCHEMBL17708375 0.80 SYK (0.67) SYKFPR2PROKR1
SCHEMBL12121012 0.80 SYK (0.67) SYKHSD17B1HSD17B2PDE4DPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187478-B2 Substituted naphthyridines and their use as medicaments Boehringer Ingellheim International GmbH (DE) 2015-11-17 US disclosed
EP-2528915-B1 SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2015-10-28 EP disclosed
US-20150126503-A1 SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INT (DE) 2015-05-07 US disclosed
US-8969568-B2 Substituted naphthyridines and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2015-03-03 US disclosed
US-8969568-B2 Substituted naphthyridines and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2015-03-03 US disclosed
US-20120028939-A1 SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-02-02 US disclosed
US-20120028939-A1 SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-02-02 US disclosed
WO-2011092128-A1 SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028939-A1 SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS NR4A3, NR0B1, NR4A1 SYK 3856/4885HSD17B1 463/4885HSD17B2 552/4885
US-20150126503-A1 SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS NR4A3, NR0B1, NR4A1 SYK 3856/4885HSD17B1 463/4885HSD17B2 552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.